NCT04283669 2026-03-13
NF110
University of Alabama at Birmingham
Phase 2 Completed
Clinical Trials
14 trialsNCT03620643 2025-10-30
ROLo
Royal Marsden NHS Foundation Trust
Phase 2 Completed
NCT02761057 2025-01-13
Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed
National Cancer Institute (NCI)
Phase 2 Completed
NCT01979536 2024-04-30
Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT02034981 2024-02-28
AcSé
UNICANCER
Phase 2 Completed
NCT01524926 2023-12-11
CREATE
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT02223819 2023-12-06
Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy
Columbia University
Phase 2 Completed
NCT02419287 2023-03-06
Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas
University of Milano Bicocca
Phase 2 Completed
NCT02183870 2022-06-16
EUCROSS
University of Cologne
Phase 2 Completed
NCT03088930 2022-02-11
Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer
University of Colorado, Denver
Phase 2 Completed
NCT01945021 2021-02-21
Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC
Pfizer
Phase 2 Completed
NCT02142036 2019-03-13
MetAction
Oslo University Hospital
Phase 2 Completed
NCT02435108 2017-02-17
A Pilot Study of Crizotinib in Patients With c-MET Positive Gastric Adenocarcinoma as a Third-line Chemotherapy
Samsung Medical Center
Phase 2 Completed
NCT00932451 2017-01-13
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Pfizer
Phase 2 Completed